Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Stemline Therapeutics, Inc.
Eli Lilly and Company
Massive Bio, Inc.
Taproot Health
BBB-Therapeutics B.V.
Novartis